BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, Ko RLW, Chan KH, Cheng SMS, Perera RAPM, Cowling BJ, Poon LLM, Peiris M. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 2021;12:63. [PMID: 33397909 DOI: 10.1038/s41467-020-20247-4] [Cited by in Crossref: 209] [Cited by in F6Publishing: 215] [Article Influence: 209.0] [Reference Citation Analysis]
Number Citing Articles
1 Favresse J, Douxfils J, Henry B, Lippi G, Plebani M. Clinical Chemistry and Laboratory Medicine celebrates 60 years – narrative review devoted to the contribution of the journal to the diagnosis of SARS-CoV-2. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-1166] [Reference Citation Analysis]
2 Garziano M, Utyro O, Strizzi S, Vanetti C, Saulle I, Conforti C, Cicilano F, Ardizzone F, Cappelletti G, Clerici M, Limanaqi F, Biasin M. Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose. IJMS 2022;23:14341. [DOI: 10.3390/ijms232214341] [Reference Citation Analysis]
3 Vangeti S, Periasamy S, Sun P, Balinsky CA, Mahajan AS, Kuzmina NA, Soares-schanoski A, Cooper E, Beckett C, Marayag J, Marrone A, Nunez E, Ge Y, Porter CK, Goforth CW, Lizewski SE, Lizewski R, Jani V, Sugiharto VA, Schilling M, Yu XB, Marjanovic N, George MC, Bukreyev A, Sealfon SC, Letizia AG, Ramos I. Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection. Microbiol Spectr 2022. [DOI: 10.1128/spectrum.01837-22] [Reference Citation Analysis]
4 Mendez-cortina Y, Rodriguez-perea AL, Chvatal-medina M, Lopera TJ, Alvarez-mesa N, Rodas-marín JK, Moncada DC, Rugeles MT, Velilla PA. Dynamics of humoral immune response in SARS-CoV-2 infected individuals with different clinical stages. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1007068] [Reference Citation Analysis]
5 Panahi Y, Einollahi B, Beiraghdar F, Darvishi M, Fathi S, Javanbakht M, Shafiee S, Akhavan-sigari R. Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.947602] [Reference Citation Analysis]
6 Ishii N, Hatakeyama S, Yoneyama T, Tanaka R, Narita T, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids. Urologic Oncology: Seminars and Original Investigations 2022;40:451.e1-451.e8. [DOI: 10.1016/j.urolonc.2022.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dzananovic B, Williamson M, Nwaigwe C, Routray C. Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota. World J Clin Infect Dis 2022; 12(2): 50-60 [DOI: 10.5495/wjcid.v12.i2.50] [Reference Citation Analysis]
8 Cao T, Liu L, To KK, Lim CY, Zhou R, Ming Y, Kwan KY, Yu S, Chan CY, Zhou B, Huang H, Mo Y, Du Z, Gong R, Yat LT, Hung IF, Tam AR, To WK, Leung WS, Chik TS, Tsang OT, Lin X, Song YQ, Yuen KY, Chen Z. Mitochondrial regulation of acute extrafollicular B-cell responses to COVID-19 severity. Clin Transl Med 2022;12:e1025. [PMID: 36103567 DOI: 10.1002/ctm2.1025] [Reference Citation Analysis]
9 Lau YL, Mu X, Cohen CA, Leung D, Duque JSR, Cheng SM, Chung Y, Wong HH, Lee AM, Li WY, Tam I, Lam JH, Lee DH, Chan SM, Tsang LC, Chan KC, Li JK, Luk LL, Chaothai S, Kwan KK, Chu NC, Mori M, Jeevan T, Kandeil A, Tu W, Valkenburg S, Peiris M. Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescents.. [DOI: 10.21203/rs.3.rs-1961385/v1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Srivastava AK, Gupta A, Chauhan D, Meena RC, Sugadev R, Eslavath MR, Gupta H, Karuna, Singh S, Singh Y, Tiwari RP, Kohli V, Varshney R, Ganju L. Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2 N and S proteins: mass screening. Appl Microbiol Biotechnol 2022. [PMID: 35976427 DOI: 10.1007/s00253-022-12113-8] [Reference Citation Analysis]
11 Misra P, Kant S, Guleria R, Rai SK, Jaiswal A, Mandal S, Medigeshi GR, Ahmad M, Rahman A, Sangral M, Yadav K, Bairwa M, Haldar P, Kumar P. Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India. Vaccines (Basel) 2022;10:1312. [PMID: 36016201 DOI: 10.3390/vaccines10081312] [Reference Citation Analysis]
12 Shim HW, Shin JH, Shin SC, Lee HJ, So KS, Lee SY, Jun JW, Seo JK, Lee HS, Lee SY, Kim SH, Kim SJ, Kim K, Ryu GH. Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test. Diagnostics 2022;12:1924. [DOI: 10.3390/diagnostics12081924] [Reference Citation Analysis]
13 Kim Y, Bae JY, Kwon K, Chang HH, Lee WK, Park H, Kim J, Choi I, Park MS, Kim SW. Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity. Sci Rep 2022;12:13491. [PMID: 35931794 DOI: 10.1038/s41598-022-17605-1] [Reference Citation Analysis]
14 Oktay E, Alem F, Hernandez K, Narayanan A, Veneziano R. DNA Origami Presenting the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Response.. [DOI: 10.1101/2022.08.02.502186] [Reference Citation Analysis]
15 De Paris K, Permar SR. Routine SARS-CoV-2 vaccination for all children. Immunol Rev 2022. [PMID: 35799475 DOI: 10.1111/imr.13108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hayer J, Urlaub E. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals. Microbiol Spectr 2022;10:e0270921. [PMID: 35575594 DOI: 10.1128/spectrum.02709-21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Alhaddad F, Abdulkareem A, Alsharrah D, Alkandari A, Bin-Hasan S, Al-Ahmad M, Al Hashemi H, Alghounaim M. Incidence of SARS-CoV-2 reinfection in a paediatric cohort in Kuwait. BMJ Open 2022;12:e056371. [PMID: 35768102 DOI: 10.1136/bmjopen-2021-056371] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, Hachim A, Zhang Y, Chan SM, Chaothai S, Kwan KKH, Chan KCK, Li JKC, Luk LLH, Tsang LCH, Wong WHS, Cheang CH, Hung TK, Lam JHY, Chua GT, Tso WWY, Ip P, Mori M, Kavian N, Leung WH, Valkenburg S, Peiris M, Tu W, Lau YL. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nat Commun 2022;13:3700. [PMID: 35764637 DOI: 10.1038/s41467-022-31485-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
19 Poehler E, Gibson L, Lustig A, Moreland NJ, Mcgregor R, James A. Estimating decay curves of neutralizing antibodies to SARS-CoV-2 infection. Mathematical Medicine and Biology: A Journal of the IMA 2022. [DOI: 10.1093/imammb/dqac008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Svorcova M, Novysedlak R, Lischke R, Vachtenheim J Jr, Strizova Z. Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety. Front Immunol 2022;13:906225. [PMID: 35720376 DOI: 10.3389/fimmu.2022.906225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Garcia-Valtanen P, Hope CM, Masavuli MG, Yeow AEL, Balachandran H, Mekonnen ZA, Al-Delfi Z, Abayasingam A, Agapiou D, Stella AO, Aggarwal A, Bouras G, Gummow J, Ferguson C, O'Connor S, McCartney EM, Lynn DJ, Maddern G, Gowans EJ, Reddi BAJ, Shaw D, Kok-Lim C, Beard MR, Weiskopf D, Sette A, Turville SG, Bull RA, Barry SC, Grubor-Bauk B. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Rep Med 2022;3:100651. [PMID: 35654046 DOI: 10.1016/j.xcrm.2022.100651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Colton H, Hodgson D, Hornsby H, Brown R, Mckenzie J, Bradley KL, James C, Lindsey BB, Birch S, Marsh L, Wood S, Bayley M, Dickson G, James DC, Nicklin MJ, Sayers JR, Zafred D, Rowland-Jones SL, Kudesia G, Kucharski A, Darton TC, de Silva TI, Collini PJ; CMMID COVID-19 Working Group. Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. Wellcome Open Res 2021;6:220. [PMID: 35600250 DOI: 10.12688/wellcomeopenres.17143.3] [Reference Citation Analysis]
23 Habibzadeh F, Habibzadeh P, Yadollahie M, Sajadi MM. Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution. Biochem med (Online) 2022;32:217-223. [DOI: 10.11613/bm.2022.020705] [Reference Citation Analysis]
24 Chen CP, Huang KA, Shih SR, Lin YC, Cheng CY, Huang YC, Lin TY, Cheng SH. Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants. Microbiol Spectr 2022;:e0074322. [PMID: 35703556 DOI: 10.1128/spectrum.00743-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Xin Q, Wu Q, Chen X, Han B, Chu K, Song Y, Jin H, Chen P, Lu W, Yang T, Li M, Zhao Y, Pan H, Yu H, Wang L. Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. Nat Commun 2022;13:3100. [PMID: 35660738 DOI: 10.1038/s41467-022-30864-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Li Y, Wang M, Wu H, Zhao H, Dong L, Li Y, Li X, Tang Y, Zhang S, Li J, Qin C, Jiang T, Deng Y, Kang X. Development of a rapid neutralizing antibody test for SARS-CoV-2 and its application for neutralizing antibody screening and vaccinated serum testing. Infectious Medicine 2022;1:95-102. [DOI: 10.1016/j.imj.2022.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Rosengarten M. Perplexity as a provocation: revisiting the role of metaphor as a ‘place holder’ for the potential of COVID-19 antibodies. Med Humanities. [DOI: 10.1136/medhum-2021-012343] [Reference Citation Analysis]
28 Clapham HE, Chia W, Zhang J, Wang L, Tam CC. SARS-CoV-2 neutralising antibody activity in a highly vaccinated population: Longitudinal serology studies in Singapore.. [DOI: 10.1101/2022.05.29.22275748] [Reference Citation Analysis]
29 Yuan H, Liang J. Modelling the impacts of public health interventions and weather on SARS-CoV-2 Omicron outbreak in Hong Kong.. [DOI: 10.1101/2022.05.25.22275487] [Reference Citation Analysis]
30 Banihashemi SR, Es-haghi A, Fallah Mehrabadi MH, Nofeli M, Mokarram AR, Ranjbar A, Salman M, Hajimoradi M, Razaz SH, Taghdiri M, Bagheri M, Dadar M, Hassan ZM, Eslampanah M, Salehi Najafabadi Z, Lotfi M, Khorasani A, Rahmani F. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models. Front Immunol 2022;13:836745. [DOI: 10.3389/fimmu.2022.836745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Tajuelo A, Carretero O, García-Ríos E, López-Siles M, Cano O, Vázquez M, Más V, Rodríguez-Goncer I, Lalueza A, López-Medrano F, Juan RS, Fernández-Ruiz M, Aguado JM, McConnell MJ, Pérez-Romero P. Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. Front Immunol 2022;13:878812. [PMID: 35547738 DOI: 10.3389/fimmu.2022.878812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Misra P, Kant S, Guleria R, Rai S, Jaiswal A, Mandal S, Medigeshi GR, Ahmad M, Rahman A, Sangral M, Yadav K, Bairwa M, Haldar P, Kumar P. Antibody response to SARS-CoV2 among COVID-19 confirmed cases, and correlates with neutralizing assay in a subgroup of patients in Delhi National Capital Region, India.. [DOI: 10.1101/2022.05.17.22275193] [Reference Citation Analysis]
33 Wirsching S, Harder L, Heymanns M, Gröndahl B, Hilbert K, Kowalzik F, Meyer C, Gehring S. Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2. Front Immunol 2022;13:800070. [PMID: 35514974 DOI: 10.3389/fimmu.2022.800070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tran TN, Wikle NB, Yang F, Inam H, Leighow S, Gentilesco B, Chan P, Albert E, Strong ER, Pritchard JR, Hanage WP, Hanks EM, Crawford FW, Boni MF. SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021. JAMA Netw Open 2022;5:e2214171. [PMID: 35616938 DOI: 10.1001/jamanetworkopen.2022.14171] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Juncker HG, Mulleners SJ, Ruhé EJM, Coenen ERM, Bakker S, van Doesburg M, Harinck JE, Rood RD, Bouhuijs JH, Oomen M, de Groot PCJM, Pajkrt PD, Korosi A, van Goudoever PJB, van Gils MJ, van Keulen BJ. Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands. EClinicalMedicine 2022;47:101393. [PMID: 35465077 DOI: 10.1016/j.eclinm.2022.101393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Ilinykh PA, Periasamy S, Huang K, Kuzmina NA, Ramanathan P, Meyer MN, Mire CE, Kuzmin IV, Bharaj P, Endsley JR, Chikina M, Sealfon SC, Widen SG, Endsley MA, Bukreyev A. A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. NPJ Vaccines 2022;7:47. [PMID: 35468973 DOI: 10.1038/s41541-022-00471-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Murrell AE, Eyoh E, Shaffer JG, Dietrich ML, Trinh IV, Yockachonis TJ, Bai S, Zheng CY, Mayne CV, Cabrera SE, Aviles-amaro A, Stone AE, Rambaran S, Chandra S, Elliott DH, Smira AR, Harris SN, Olson KE, Bilton SJ, Gabriel MJ, Falgout ND, Engel EJ, Prystowsky AD, Ning B, Hu T, Kolls JK, Landry SJ, Drury SS, Schieffelin JS, Zwezdaryk KJ, Robinson JE, Gunn BM, Norton EB. Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age.. [DOI: 10.1101/2022.04.22.22274032] [Reference Citation Analysis]
38 Qaqish A, Abbas MM, Al-tamimi M, Abbas MA, Al-omari M, Alqassieh R. SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals. Vaccines 2022;10:643. [DOI: 10.3390/vaccines10050643] [Reference Citation Analysis]
39 Lee B, Ko J, Park J, Moon H, Baek JY, Jung S, Lim H, Kim K, Huh K, Cho SY, Kang C, Chung DR, Huh HJ, Chung CR, Kim Y, Joo E, Kang E, Peck KR. Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. Front Cell Infect Microbiol 2022;12:822599. [DOI: 10.3389/fcimb.2022.822599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
40 Kaneko Y, Sugiyama A, Tanaka T, Fukui K, Taguchi A, Tatsuno K, Nakayama A, Koga K, Kishi Y, Daming W, Qian C, Xia F, He F, Zheng L, Yu Y, Wada Y, Wada Y, Kodama T, Kawamura T. The serological diversity of serum IgG/IgA/IgM against SARS‐CoV‐2 nucleoprotein, spike, and receptor‐binding domain and neutralizing antibodies in patients with COVID‐19 in Japan. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, Gu Y, Guo Y, Lv J, Huang Y, Liu Y, Xu D, Chen S, Li J, Li Q, Liang J, Bian L, Zhang Z, Guo X, Feng Y, Liu L, Zhang X, Zhang Y, Xie F, Jiang S, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhu Y, Cong Q, Xu J, Hou Z, Zhang N, Zhang A, Zu H, Wang Y, Yan Z, Du X, Hou A, Yan Y, Qiu Y, Wu H, Hu S, Deng Y, Ji J, Yang J, Huang J, Zhao Z, Zou S, Ji H, Ge G, Zhong L, He S, Yan X, Yangzhen BB, Qu C, Zhang L, Yang S, Gao X, Lv M, Zhu Q, Xu X, Zeng Q, Qi X, Zhang W. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. [DOI: 10.1007/s12072-022-10332-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 Hamaya T, Hatakeyama S, Yoneyama T, Tobisawa Y, Kodama H, Fujita T, Murakami R, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Saitoh H, Narumi S, Tomita H, Ohyama C. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients. Sci Rep 2022;12:5876. [PMID: 35393481 DOI: 10.1038/s41598-022-09897-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 Teplensky MH, Distler ME, Kusmierz CD, Evangelopoulos M, Gula H, Elli D, Tomatsidou A, Nicolaescu V, Gelarden I, Yeldandi A, Batlle D, Missiakas D, Mirkin CA. Spherical nucleic acids as an infectious disease vaccine platform. Proc Natl Acad Sci U S A 2022;119:e2119093119. [PMID: 35312341 DOI: 10.1073/pnas.2119093119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Chen Z, Zheng W, Wu Q, Chen X, Peng C, Tian Y, Sun R, Dong J, Wang M, Zhou X, Zhao Z, Zhong G, Yan X, Liu N, Hao F, Zhao S, Zhuang T, Yang J, Azman AS, Yu H. Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study. BMC Med 2022;20:130. [PMID: 35369871 DOI: 10.1186/s12916-022-02333-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
45 Chaves DG, de Oliveira LC, da Silva Malta MCF, de Oliveira IR, Barbosa-Stancioli EF, Teixeira MM, Martins ML. Pro-inflammatory immune profile mediated by TNF and IFN-γ and regulated by IL-10 is associated to IgG anti-SARS-CoV-2 in asymptomatic blood donors. Cytokine 2022;154:155874. [PMID: 35397248 DOI: 10.1016/j.cyto.2022.155874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet J, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-lamm A, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F. Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study. European Journal of Cancer 2022;165:13-24. [DOI: 10.1016/j.ejca.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Togashi K, Hatakeyama S, Yoneyama T, Hamaya T, Narita T, Fujita N, Iwamura H, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma. Int J Urol 2022. [PMID: 35362143 DOI: 10.1111/iju.14882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
48 Muskiet FAJ, Carrera-bastos P, Pruimboom L, Lucia A, Furman D. Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19. Nutrients 2022;14:1388. [DOI: 10.3390/nu14071388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
49 Cantoni D, Mayora-Neto M, Nadesalingam A, Wells DA, Carnell GW, Ohlendorf L, Ferrari M, Palmer P, Chan ACY, Smith P, Bentley EM, Einhauser S, Wagner R, Page M, Raddi G, Baxendale H, Castillo-Olivares J, Heeney J, Temperton N. Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. Front Immunol 2022;13:773982. [PMID: 35330908 DOI: 10.3389/fimmu.2022.773982] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
50 Shinada K, Sato T, Moriyama S, Adachi Y, Shinoda M, Ota S, Morikawa M, Mineshita M, Matsumura T, Takahashi Y, Shinkai M. Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir. Viruses 2022;14:670. [DOI: 10.3390/v14040670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Fung K, Lai S, Lin T, Tseng T. Antigen–Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. Front Mol Biosci 2022;9:797132. [DOI: 10.3389/fmolb.2022.797132] [Reference Citation Analysis]
52 Yan LN, Liu PP, Li XG, Zhou SJ, Li H, Wang ZY, Shen F, Lu BC, Long Y, Xiao X, Wang ZD, Li D, Han HJ, Yu H, Zhou SH, Lv WL, Yu XJ. Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection. Front Microbiol 2021;12:803031. [PMID: 35310397 DOI: 10.3389/fmicb.2021.803031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
53 Kowalski E, Stengel A, Schneider A, Goebel-stengel M, Zipfel S, Graf J. How to Motivate SARS-CoV-2 Convalescents to Receive a Booster Vaccination? Influence on Vaccination Willingness. Vaccines 2022;10:455. [DOI: 10.3390/vaccines10030455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Álvarez-díaz DA, Muñoz AL, Herrera-sepúlveda MT, Tavera-rodríguez P, Laiton-donato K, Franco-muñoz C, Ruiz-moreno HA, Pelaez-carvajal D, Muñoz-suarez AM, Galindo M, Reales-gonzalez J, Catama JD, De Arco BH, Cobos T, Arias-ramirez EJ, Mercado-reyes M. Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021.. [DOI: 10.1101/2022.03.15.22272371] [Reference Citation Analysis]
55 Colton H, Hodgson D, Hornsby H, Brown R, Mckenzie J, Bradley KL, James C, Lindsey BB, Birch S, Marsh L, Wood S, Bayley M, Dickson G, James DC, Nicklin MJ, Sayers JR, Zafred D, Rowland-jones SL, Kudesia G, Kucharski A, Darton TC, de Silva TI, Collini PJ; CMMID COVID-19 Working Group. Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. Wellcome Open Res 2021;6:220. [DOI: 10.12688/wellcomeopenres.17143.2] [Reference Citation Analysis]
56 Suzuki Y. Estimating antigenic distances between GII.4 human norovirus strains. Gene Reports 2022;26:101492. [DOI: 10.1016/j.genrep.2021.101492] [Reference Citation Analysis]
57 Li W, Meng J, Ma X, Lin J, Lu X. Advanced materials for the delivery of vaccines for infectious diseases. Biosafety and Health 2022. [DOI: 10.1016/j.bsheal.2022.03.002] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Kay GA, Owen SI, Giorgi E, Clark DJ, Williams CT, Menzies S, Cuevas LE, Davies BMO, Eckersley NM, Hughes GL, Kirwan DE, Krishna S, Patterson EI, Planche T, Staines HM, Adams ER. SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests. Sci Rep 2022;12:3351. [PMID: 35233014 DOI: 10.1038/s41598-022-07263-8] [Reference Citation Analysis]
59 Bellier B, Saura A, Luján LA, Molina CR, Luján HD, Klatzmann D. A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity. Front Immunol 2022;13:837443. [DOI: 10.3389/fimmu.2022.837443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 de-Oliveira-Pinto LM, Fiestas Solórzano VE, de Lourdes Martins M, Fernandes-Santos C, Damasco PH, de Siqueira MAMT, Dias HG, Pauvolid-Corrêa A, Damasco PV, de Azeredo EL. Comparative Analysis of Circulating Levels of SARS-CoV-2 Antibodies and Inflammatory Mediators in Healthcare Workers and COVID-19 Patients. Viruses 2022;14:455. [PMID: 35336861 DOI: 10.3390/v14030455] [Reference Citation Analysis]
61 Zhang S, Xu K, Li C, Zhou L, Kong X, Peng J, Zhu F, Bao C, Jin H, Gao Q, Zhao X, Zhu L. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Front Immunol 2022;13:829665. [PMID: 35154152 DOI: 10.3389/fimmu.2022.829665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
62 Arora S, Grover V, Saluja P, Algarni YA, Saquib SA, Asif SM, Batra K, Alshahrani MY, Das G, Jain R, Ohri A. Literature Review of Omicron: A Grim Reality Amidst COVID-19. Microorganisms 2022;10:451. [DOI: 10.3390/microorganisms10020451] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
63 Jonczyk R, Stanislawski N, Seiler LK, Blume H, Heiden S, Lucas H, Sarikouch S, Pott PC, Stiesch M, Hauß C, Saletti G, González-Hernández M, Kaiser FK, Rimmelzwaan G, Osterhaus A, Blume C. Combined Prospective Seroconversion and PCR Data of Selected Cohorts Indicate a High Rate of Subclinical SARS-CoV-2 Infections-an Open Observational Study in Lower Saxony, Germany. Microbiol Spectr 2022;:e0151221. [PMID: 35171028 DOI: 10.1128/spectrum.01512-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
64 Cheong J, Ravishankar A, Sharma S, Parkhurst CN, Nehar-belaid D, Ma S, Paddock L, Fatou B, Karakaslar O, Thibodeau A, Bale MJ, Kartha VK, Yee JK, Mays MY, Leyre L, de Paz AM, Daman AW, Mullett SA, Robbins L, Lafond E, Weidman K, Racine-brzostek S, Yang HS, Price D, Jones B, Schenck EJ, Kaner RJ, Chadburn A, Zhao Z, Steen H, Pascual V, Buenrostro J, Niec RE, Lief L, Ucar D, Josefowicz SZ. Epigenetic Memory of COVID-19 in Innate Immune Cells and Their Progenitors.. [DOI: 10.1101/2022.02.09.479588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Huang R, Fu Y, Wang Y, Hong C, Yang W, Wang I, Sun J, Chen Y, Shen C, Cheng C. A Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader for SARS-CoV-2 Neutralizing Antibody Detection. Vaccines 2022;10:271. [DOI: 10.3390/vaccines10020271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
66 Toth D. Neutralization Of SARS-CoV-2 Variants By A Human Polyclonal Antibody Therapeutic (COVID-HIG, NP-028) With High Neutralizing Titers To SARS-CoV-2.. [DOI: 10.1101/2022.01.27.478053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, Guo L, Li X, Li J, Wang J, Li M, Xu Z, Zhang M, Wang F, Shi Y, Yuan J, Liu Y. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat Microbiol 2022. [PMID: 35132197 DOI: 10.1038/s41564-021-01051-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 19.0] [Reference Citation Analysis]
68 Zhou W, He P, Li J, Liu H, Shi M, Yu J, Wei H. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera. Viruses 2022;14:335. [DOI: 10.3390/v14020335] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
69 Wiwe EF, Carlsson ER, Rasmussen CL, Rasmussen P, Ougaard R, Hansen SI, Schiøler T, Kristiansen S, Hansen YB, Hillig T. Long-Term Comparison of 7 SARS-CoV-2 Antibody Assays in the North Zealand Covid-19 Cohort. The Journal of Applied Laboratory Medicine 2022. [DOI: 10.1093/jalm/jfab173] [Reference Citation Analysis]
70 Jawalagatti V, Kirthika P, Park J, Hewawaduge C, Lee JH. Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection. Journal of Advanced Research 2022;36:211-22. [DOI: 10.1016/j.jare.2021.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
71 Van Elslande J, Oyaert M, Lorent N, Weygaerde YV, Van Pottelbergh G, Godderis L, Van Ranst M, André E, Padalko E, Lagrou K, Vandendriessche S, Vermeersch P. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease 2022. [DOI: 10.1016/j.diagmicrobio.2022.115659] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
72 Gentles LE, Kehoe L, Crawford KHD, Lacombe K, Dickerson J, Wolf C, Yuan J, Schuler S, Watson JT, Nyanseor S, Briggs-Hagen M, Saydah S, Midgley CM, Pringle K, Chu H, Bloom JD, Englund JA. Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time. medRxiv 2022:2022. [PMID: 35118481 DOI: 10.1101/2022.01.14.22269235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
73 Chivu-Economescu M, Bleotu C, Grancea C, Chiriac D, Botezatu A, Iancu IV, Pitica I, Necula LG, Neagu A, Matei L, Dragu D, Sultana C, Radu EL, Nastasie A, Voicu O, Ataman M, Nedeianu S, Mambet C, Diaconu CC, Ruta SM. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19. J Cell Mol Med 2022. [PMID: 35043552 DOI: 10.1111/jcmm.17186] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
74 Hogan AB, Wu SL, Doohan P, Watson OJ, Winskill P, Charles G, Barnsley G, Riley EM, Khoury DS, Ferguson NM, Ghani AC. The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant.. [DOI: 10.1101/2022.01.17.22269222] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
75 Peng KW, Carey T, Lech P, Vandergaast R, Muñoz-Alía MÁ, Packiriswamy N, Gnanadurai C, Krotova K, Tesfay M, Ziegler C, Haselton M, Sevola K, Lathrum C, Reiter S, Narjari R, Balakrishnan B, Suksanpaisan L, Sakuma T, Recker J, Zhang L, Waniger S, Russell L, Petro CD, Kyratsous CA, Baum A, Janecek JL, Lee RM, Ramachandran S, Graham ML, Russell SJ. Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine. Vaccine 2022:S0264-410X(21)01671-6. [PMID: 35282925 DOI: 10.1016/j.vaccine.2021.12.063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
76 Gupta SL, Jaiswal RK. Neutralizing antibody: a savior in the Covid-19 disease. Mol Biol Rep 2022;49:2465-74. [PMID: 34988889 DOI: 10.1007/s11033-021-07020-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Varghese S, Sachu A, Jacob L, George G, Chandy G, Samuel Johnson A, John G. COVID-19 vaccines portray the bright side of human creativity, but it means nothing until they prove their worth: A Study on Seroconversion after the first Dose of Covishield vaccine in central Kerala. Indian J Community Med 2022;47:213. [DOI: 10.4103/ijcm.ijcm_671_21] [Reference Citation Analysis]
78 Kumar A, Krishna A, Singh P, Patel P. Reinfection of SARS-CoV-2 in kidney transplant recipient. Indian J Transplant 2022;16:234. [DOI: 10.4103/ijot.ijot_74_21] [Reference Citation Analysis]
79 Cedillo-barrón L, García-cordero J, Mendoza-ramírez N, Martínez-frías S. Overview of the immune response against SARS-CoV-2. Biomedical Innovations to Combat COVID-19 2022. [DOI: 10.1016/b978-0-323-90248-9.00004-8] [Reference Citation Analysis]
80 Frasca D. Effects of Aging and Associated Conditions on Humoral Responses to Respiratory Tract Infections. Healthy Ageing and Longevity 2022. [DOI: 10.1007/978-3-030-87532-9_5] [Reference Citation Analysis]
81 He L, Zeng C, Zeng Y, Xu W, Li Y, Xie X, Xu W, Xia H, Tang F, Tang S, Xu L, Chen C. Antibody Responses of the First Wave of Survivors infected with SARS-CoV-2 One Year Ago. J Med Virol 2021. [PMID: 34952979 DOI: 10.1002/jmv.27551] [Reference Citation Analysis]
82 Valcourt EJ, Manguiat K, Robinson A, Lin YC, Abe KT, Mubareka S, Shigayeva A, Zhong Z, Girardin RC, DuPuis A, Payne A, McDonough K, Wang Z, Gasser R, Laumaea A, Benlarbi M, Richard J, Prévost J, Anand SP, Dimitrova K, Phillipson C, McGeer A, Gingras AC, Liang C, Petric M, Sekirov I, Morshed M, Finzi A, Drebot M, Wood H. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays. Microbiol Spectr 2021;9:e0088621. [PMID: 34787495 DOI: 10.1128/Spectrum.00886-21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
83 Hayer J, Urlaub E. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in samples from vaccinated individuals.. [DOI: 10.1101/2021.12.17.21267927] [Reference Citation Analysis]
84 Abidi SH, Imtiaz K, Kanji A, Qaiser S, Khan E, Iqbal K, Veldhoen M, Ghias K, Simas JP, Hasan Z. A rapid real-time polymerase chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against SARS-CoV-2 in blood/serum. PLoS One 2021;16:e0259551. [PMID: 34890401 DOI: 10.1371/journal.pone.0259551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Melani RD, Des Soye BJ, Kafader JO, Forte E, Hollas M, Blagojevic V, Negrão F, McGee JP, Drown B, Lloyd-Jones C, Seckler HS, Camarillo JM, Compton PD, LeDuc RD, Early B, Fellers RT, Cho BK, Mattamana BB, Goo YA, Thomas PM, Ash MK, Bhimalli PP, Al-Harthi L, Sha BE, Schneider JR, Kelleher NL. Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire. J Proteome Res 2021. [PMID: 34878788 DOI: 10.1021/acs.jproteome.1c00882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine 2021;74:103729. [PMID: 34871960 DOI: 10.1016/j.ebiom.2021.103729] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
87 Tran TN, Wikle NB, Yang F, Inam H, Leighow S, Gentilesco B, Chan P, Albert E, Strong ER, Pritchard JR, Hanage WP, Hanks EM, Crawford FW, Boni MF. SARS-CoV-2 attack rate and population immunity in southern New England, March 2020 - May 2021.. [DOI: 10.1101/2021.12.06.21267375] [Reference Citation Analysis]
88 Castillo-Olivares J, Wells DA, Ferrari M, Chan ACY, Smith P, Nadesalingam A, Paloniemi M, Carnell GW, Ohlendorf L, Cantoni D, Mayora-Neto M, Palmer P, Tonks P, Temperton NJ, Peterhoff D, Neckermann P, Wagner R, Doffinger R, Kempster S, Otter AD, Semper A, Brooks T, Albecka A, James LC, Page M, Schwaeble W, Baxendale H, Heeney JL. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. Front Immunol 2021;12:748291. [PMID: 34867975 DOI: 10.3389/fimmu.2021.748291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
89 Karuna S, Li SS, Grant S, Walsh SR, Frank I, Casapia M, Trahey M, Hyrien O, Fisher L, Miner MD, Randhawa AK, Polakowski L, Kublin JG, Corey L, Montefiori D; HVTN 405/HPTN 1901 Study Team. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. PLoS Med 2021;18:e1003868. [PMID: 34871308 DOI: 10.1371/journal.pmed.1003868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
90 Pignolo A, Aprile M, Gagliardo C, Giammanco GM, D'Amelio M, Aridon P, La Tona G, Salemi G, Ragonese P. Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection. Neurol Int 2021;13:695-700. [PMID: 34940752 DOI: 10.3390/neurolint13040066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
91 Olariu TR, Ursoniu S, Marincu I, Lupu MA. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study. Medicina (Kaunas) 2021;57:1330. [PMID: 34946275 DOI: 10.3390/medicina57121330] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
92 Padma MR, Dinesh P, Sundaresan R, Athreya S, Shiju S, Maroor PS, Hande RL, Akhtar J, Chandra T, Ravi D, Lobo E, Ana Y, Shriyan P, Desai A, Rangaiah A, Munivenkatappa A, Krishna S, Basawarajappa SG, Sreedhara H, Siddesh K, Amrutha Kumari B, Umar N, Mythri B, Mythri K, Sudarshan MK, Vasanthapuram R, Babu GR. Second round statewide sentinel-based population survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India, during January-February 2021. IJID Regions 2021;1:107-116. [DOI: 10.1016/j.ijregi.2021.10.008] [Reference Citation Analysis]
93 Stein RA, Ometa O, Broker TR. COVID-19: The Pseudo-Environment and the Need for a Paradigm Change. Germs 2021;11:468-77. [PMID: 35096665 DOI: 10.18683/germs.2021.1283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
94 Gilboa T, Cohen L, Cheng C, Lazarovits R, Uwamanzu‐nna A, Han I, Griswold K, Barry N, Thompson DB, Kohman RE, Woolley AE, Karlson EW, Walt DR. A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays. Angewandte Chemie 2021;133:26170-26176. [DOI: 10.1002/ange.202110702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
95 Lin Q, Wu J, Liu L, Wu W, Fang X, Kong J. Sandwich/competitive immuno-sensors on micro-interface for SARS-CoV-2 neutralizing antibodies. Anal Chim Acta 2021;1187:339144. [PMID: 34753584 DOI: 10.1016/j.aca.2021.339144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
96 Wang LL, Yang JW, Xu JF. Coronavirus (SARS-CoV-2) causes lung inflammation and injury. Clin Microbiol Infect 2021:S1198-743X(21)00674-1. [PMID: 34861410 DOI: 10.1016/j.cmi.2021.11.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
97 Jung BK, Yoon J, Bae JY, Kim J, Park MS, Lee SY, Lim CS. Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies. Diagnostics (Basel) 2021;11:2193. [PMID: 34943430 DOI: 10.3390/diagnostics11122193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines (Basel) 2021;9:1376. [PMID: 34960121 DOI: 10.3390/vaccines9121376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
99 Kruse RL, Huang Y, Lee A, Zhu X, Shrestha R, Laeyendecker O, Littlefield K, Pekosz A, Bloch EM, Tobian AAR, Wang ZZ. A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. J Clin Microbiol 2021;59:e0118621. [PMID: 34469185 DOI: 10.1128/JCM.01186-21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
100 Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res 2021:S1931-5244(21)00269-3. [PMID: 34780969 DOI: 10.1016/j.trsl.2021.11.006] [Reference Citation Analysis]
101 Buckley A, Mills A, Paul K, Raymond S, Mendu DR, DeBolt C, Rosenberg M, Wajnberg A, Szeto L, Cochrane E, Vieira L, Berkin J, Ferrera L, Stone J, Bianco A. SARS-CoV-2 Antibody Response among Women Infected during Pregnancy. Am J Perinatol 2021. [PMID: 34768307 DOI: 10.1055/s-0041-1739469] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Garcia-valtanen P, Hope CM, Masavuli MG, Lip Yeow AE, Balachandran H, Mekonnen ZA, Al-delfi Z, Abayasingam A, Agapiou D, Stella AO, Aggarwal A, Gummow J, Ferguson C, O’connor S, Mccartney EM, Lynn DJ, Maddern G, Gowans EJ, Reddi BA, Shaw D, Kok-lim C, Turville SG, Beard MR, Weiskopf D, Sette A, Bull RA, Barry SC, Grubor-bauk B. COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection.. [DOI: 10.1101/2021.11.08.21266035] [Reference Citation Analysis]
103 Lau EH, Hui DS, Tsang OT, Chan WH, Kwan MY, Chiu SS, Cheng SM, Ko RL, Li JK, Chaothai S, Tsang CH, Poon LL, Peiris M. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine 2021;41:101174. [PMID: 34746725 DOI: 10.1016/j.eclinm.2021.101174] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 26.0] [Reference Citation Analysis]
104 Mileto D, Fenizia C, Cutrera M, Gagliardi G, Gigantiello A, De Silvestri A, Rizzo A, Mancon A, Bianchi M, De Poli F, Cuomo M, Burgo I, Longo M, Rimoldi SG, Pagani C, Grosso S, Micheli V, Rizzardini G, Biasin M, Gismondo MR, Lombardi A. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response. Emerg Microbes Infect 2021;:1-29. [PMID: 34749573 DOI: 10.1080/22221751.2021.2004866] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
105 Müller L, Andrée M, Ostermann PN, Jazmati N, Flüh G, Fischer JC, Bölke E, Heger E, Vanshylla K, Klein F, Wisplinghoff H, Schaal H, Drexler I, Walker A, Adams O, Timm J. SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response. Front Med (Lausanne) 2021;8:746644. [PMID: 34708057 DOI: 10.3389/fmed.2021.746644] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Larese Filon F, Purpuri A, Camata D, Bovenzi M, Rui F, Ronchese F, De Michieli P, Marcello A, Poggianella M, Confalonieri M, Salton F, Confalonieri P, Ruscio M, Belgrano A, Segat L, D'Agaro P, Negro C. Low sensitivity of rapid tests detecting anti-CoV-2 IgG and IgM in health care workers' serum for COVID-19 screening. Med Lav 2021;112:331-9. [PMID: 34726663 DOI: 10.23749/mdl.v112i5.11798] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Chen Z, Zheng W, Wu Q, Chen X, Peng C, Tian Y, Sun R, Wang M, Zhou X, Zhao Z, Zhong G, Yan X, Liu N, Hao F, Zhao S, Zhuang T, Yang J, Azman AS, Yu H. Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.. [DOI: 10.1101/2021.10.25.21265504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Liu J, Wang J, Xu J, Xia H, Wang Y, Zhang C, Chen W, Zhang H, Liu Q, Zhu R, Shi Y, Shen Z, Xing Z, Gao W, Zhou L, Shao J, Shi J, Yang X, Deng Y, Wu L, Lin Q, Zheng C, Zhu W, Wang C, Sun YE, Liu Z. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov 2021;7:99. [PMID: 34697287 DOI: 10.1038/s41421-021-00329-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 16.0] [Reference Citation Analysis]
109 Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, Ward T. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir Med 2021:S2213-2600(21)00407-0. [PMID: 34688434 DOI: 10.1016/S2213-2600(21)00407-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 55.0] [Reference Citation Analysis]
110 Guzmán-Martínez O, Guardado K, Varela-Cardoso M, Trujillo-Rivera A, Marín-Hernández A, Ortiz-León MC, Gómez-Ñañez I, Gutiérrez M, Espinosa R, Sampieri CL, Ramos C, López-Guerrero DV, Zenteno-Cuevas R, Pérez-Carreón JI, Canales-Vázquez G, Montero H. Generation and persistence of S1 IgG and neutralizing antibodies in post-COVID-19 patients. Infection 2021. [PMID: 34668145 DOI: 10.1007/s15010-021-01705-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
111 Peng K, Carey T, Lech P, Vandergaast R, Muñoz-alía MÁ, Packiriswamy N, Gnanadurai C, Krotova K, Tesfay M, Ziegler C, Haselton M, Sevola K, Lathrum C, Reiter S, Narjari R, Balakrishnan B, Suksanpaisan L, Sakuma T, Recker J, Zhang L, Waniger S, Russell L, Petro CD, Kyratsous CA, Baum A, Janecek JL, Lee RM, Ramachandran S, Graham ML, Russell SJ. Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.. [DOI: 10.1101/2021.10.16.464660] [Reference Citation Analysis]
112 Barnes TW, Schulte-Pelkum J, Steller L, Filchtinski D, Jenness R, Williams MR, Kober C, Manni S, Hauser T, Hahn A, Kalina U, Simon TL, Schuetz P, Roth NJ. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors. Clin Immunol 2021;232:108871. [PMID: 34619377 DOI: 10.1016/j.clim.2021.108871] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
113 Cappuccilli M, Bruno PF, Spazzoli A, Righini M, Flachi M, Semprini S, Grumiro L, Marino MM, Schiavone P, Fabbri E, Fantini M, Buscaroli A, Rigotti A, La Manna G, Sambri V, Mosconi G. Persistence of Antibody Responses to the SARS-CoV-2 in Dialysis Patients and Renal Transplant Recipients Recovered from COVID-19. Pathogens 2021;10:1289. [PMID: 34684237 DOI: 10.3390/pathogens10101289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
114 Sariol CAA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina-Rodríguez A, Cruz L, Stone ETT, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AKK, Brien JDD, Espino AMM. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. Viruses 2021;13:1972. [PMID: 34696403 DOI: 10.3390/v13101972] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
115 Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, Guo L, Li X, Li J, Wang J, Li M, Xu Z, Zhang M, Wang F, Shi Y, Yuan J, Liu Y. Persistent while declined neutralizing antibody responses in the convalescents of COVID-19 across clinical spectrum during the 16 months follow up.. [DOI: 10.1101/2021.09.18.21263550] [Reference Citation Analysis]
116 Feng Y, Zhang Y, He Z, Huang H, Tian X, Wang G, Chen D, Ren Y, Jia L, Wang W, Wu J, Shao L, Zhang W, Tang H, Wan Y. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV-1.. [DOI: 10.1101/2021.09.14.21263556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Schuh W, Baus L, Steinmetz T, Schulz SR, Weckwerth L, Roth E, Hauke M, Krause S, Morhart P, Rauh M, Hoffmann M, Vesper N, Reth M, Schneider H, Jäck HM, Mielenz D. A surrogate cell-based SARS-CoV-2 spike blocking assay. Eur J Immunol 2021;51:2665-76. [PMID: 34547822 DOI: 10.1002/eji.202149302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
118 Dittadi R, Seguso M, Bertoli I, Afshar H, Carraro P. Antibodies against SARS-CoV-2 Time Course in Patients and Vaccinated Subjects: An Evaluation of the Harmonization of Two Different Methods. Diagnostics (Basel) 2021;11:1709. [PMID: 34574052 DOI: 10.3390/diagnostics11091709] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
119 Gilboa T, Cohen L, Cheng CA, Lazarovits R, Uwamanzu-Nna A, Han I, Griswold K Jr, Barry N, Thompson DB, Kohman RE, Woolley AE, Karlson EW, Walt DR. A SARS-CoV-2 Neutralization Assay Using Single Molecule Arrays. Angew Chem Int Ed Engl 2021. [PMID: 34534408 DOI: 10.1002/anie.202110702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
120 Psichogiou M, Karabinis A, Poulakou G, Antoniadou A, Kotanidou A, Degiannis D, Pavlopoulou ID, Chaidaroglou A, Roussos S, Mastrogianni E, Eliadi I, Basoulis D, Petsios K, Leontis K, Kakalou E, Protopapas K, Jahaj E, Pratikaki M, Syrigos KN, Lagiou P, Gogas H, Tsiodras S, Magiorkinis G, Paraskevis D, Sypsa V, Hatzakis A. Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines (Basel) 2021;9:1017. [PMID: 34579254 DOI: 10.3390/vaccines9091017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
121 Bellier B, Saura A, Luján LA, Molina CR, Lujan HD, Klatzmann D. A thermostable oral SARS-CoV-2 vaccine induces mucosal and protective immunity.. [DOI: 10.1101/2021.09.09.459634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Danese E, Montagnana M, Salvagno GL, Gelati M, Peserico D, Pighi L, de Nitto S, Henry BM, Porru S, Lippi G. Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA. J Med Biochem 2021;40:335-40. [PMID: 34616223 DOI: 10.5937/jomb0-31475] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
123 Colton H, Hodgson D, Hornsby H, Brown R, Mckenzie J, Bradley KL, James C, Lindsey BB, Birch S, Marsh L, Wood S, Bayley M, Dickson G, James DC, Nicklin M, Sayers JR, Zafred D, Rowland-jones SL, Kudesia G, Kucharski A, Darton TC, de Silva TI, Collini PJ; CMMID COVID-19 Working Group. Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. Wellcome Open Res 2021;6:220. [DOI: 10.12688/wellcomeopenres.17143.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
124 Caniels TG, Bontjer I, van der Straten K, Poniman M, Burger JA, Appelman B, Lavell HAA, Oomen M, Godeke GJ, Valle C, Mögling R, van Willigen HDG, Wynberg E, Schinkel M, van Vught LA, Guerra D, Snitselaar JL, Chaturbhuj DN, Cuella Martin I, Moore JP, de Jong MD, Reusken C, Sikkens JJ, Bomers MK, de Bree GJ, van Gils MJ, Eggink D, Sanders RW; Amsterdam UMC COVID-19 S3/HCW study group. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Sci Adv 2021;7:eabj5365. [PMID: 34516917 DOI: 10.1126/sciadv.abj5365] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 37.0] [Reference Citation Analysis]
125 Tosta E. The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. Explor Immunol. [DOI: 10.37349/ei.2021.00014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
126 Pang NY, Pang AS, Chow VT, Wang DY. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res 2021;8:47. [PMID: 34465396 DOI: 10.1186/s40779-021-00342-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 38] [Article Influence: 28.0] [Reference Citation Analysis]
127 Dittadi R, Seguso M, Bertoli I, Afshar H, Carraro P. Antibodies anti-SARS-CoV2 time-course in patients and vaccinated subjects: an evaluation of the harmonization of two different methods.. [DOI: 10.1101/2021.08.28.21262543] [Reference Citation Analysis]
128 Thakkar A, Mishra S, Warner JL. COVID-19 Vaccine among Actively-Treated People with Cancer: A Glimpse into the Known Unknowns? J Natl Cancer Inst 2021:djab175. [PMID: 34453849 DOI: 10.1093/jnci/djab175] [Reference Citation Analysis]
129 Huang SW, Urbina AN, Chen YA, Wang SF. A Retrospective Survey among SARS-CoV-1 Infected Healthcare Workers after Three Years Post-Infection. Pathogens 2021;10:1078. [PMID: 34578111 DOI: 10.3390/pathogens10091078] [Reference Citation Analysis]
130 Sun L, Warner JL, Parikh RB. Immune Responses to SARS-CoV-2 Among Patients With Cancer: What Can Seropositivity Tell Us? JAMA Oncol 2021;7:1123-5. [PMID: 34047766 DOI: 10.1001/jamaoncol.2021.2096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
131 Smerczak E. SARS-CoV-2 Antibody Testing: Where Are We Now? Lab Med 2021:lmab061. [PMID: 34410405 DOI: 10.1093/labmed/lmab061] [Reference Citation Analysis]
132 Peng P, Deng HJ, Hu J, Wei XY, Xue JJ, Li TT, Fang L, Liu BZ, Jin AS, Xu FL, Wu K, Long QX, Chen J, Wang K, Tang N, Huang AL. Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine. Cell Discov 2021;7:68. [PMID: 34400614 DOI: 10.1038/s41421-021-00311-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
133 Lynch SA, Subbarao K, Mahanty S, Barber BE, Roulis EV, van der Hoek L, McCarthy JS, Spann KM. Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia. Viruses 2021;13:1618. [PMID: 34452482 DOI: 10.3390/v13081618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Mouton W, Compagnon C, Saker K, Daniel S, Djebali S, Lacoux X, Pozzetto B, Oriol G, Laubreton D, Prieux M, Fassier JB, Guibert N, Massardier-Pilonchéry A, Alfaiate D, Berthier F, Walzer T, Marvel J, Brengel-Pesce K, Trouiller-Assant S. Specific detection of memory T-cells in COVID-19 patients using standardized whole-blood Interferon gamma release assay. Eur J Immunol 2021. [PMID: 34387859 DOI: 10.1002/eji.202149296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Havervall S, Marking U, Gordon M, Ng H, Greilert-norin N, Lindbo S, Blom K, Nilsson P, Phillipson M, Klingström J, Mangsbo S, Åberg M, Hober S, Thålin C. Neutralization of VOCs including Delta one year post COVID-19 or vaccine.. [DOI: 10.1101/2021.08.12.21261951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
136 Sariol CA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina A, Cruz L, Stone ET, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AK, Brien JD, Espino AM. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. medRxiv 2021:2021. [PMID: 34100029 DOI: 10.1101/2021.06.02.21257975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
137 Bobdey S, Kaushik SK, Menon AS. The conundrum of two-dose interval of ChAdOx1 nCOV-19 corona virus vaccine: Way ahead. Med J Armed Forces India 2021;77:S250-3. [PMID: 34334889 DOI: 10.1016/j.mjafi.2021.05.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Ali AM, Ali KM, Fatah MH, Tawfeeq HM, Rostam HM. SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19. New Microbes New Infect 2021;43:100926. [PMID: 34367645 DOI: 10.1016/j.nmni.2021.100926] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 20.0] [Reference Citation Analysis]
139 Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Donatelli J, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J Jr, Trinh L, Wrin T, Petropoulos CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv 2021;7:eabh3409. [PMID: 34330709 DOI: 10.1126/sciadv.abh3409] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 64.0] [Reference Citation Analysis]
140 Cohen CA, Li APY, Hachim A, Hui DSC, Kwan MYW, Tsang OTY, Chiu SS, Chan WH, Yau YS, Kavian N, Ma FNL, Lau EHY, Cheng SMS, Poon LLM, Peiris M, Valkenburg SA. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. Nat Commun 2021;12:4678. [PMID: 34326343 DOI: 10.1038/s41467-021-24938-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 35.0] [Reference Citation Analysis]
141 Hamady A, Lee J, Loboda ZA. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection 2021. [PMID: 34324165 DOI: 10.1007/s15010-021-01664-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 21.0] [Reference Citation Analysis]
142 Chong ZX, Liew WPP, Ong HK, Yong CY, Shit CS, Ho WY, Ng SYL, Yeap SK. Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pathol Res Pract 2021;225:153565. [PMID: 34333398 DOI: 10.1016/j.prp.2021.153565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Lombardi A, Consonni D, Oggioni M, Bono P, Uceda Renteria S, Piatti A, Pesatori AC, Castaldi S, Muscatello A, Riboldi L, Ceriotti F, Bandera A, Gori A. SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals. J Infect Public Health 2021;14:1120-2. [PMID: 34293641 DOI: 10.1016/j.jiph.2021.07.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
144 Tsai KC, Lee YC, Tseng TS. Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies. Front Microbiol 2021;12:698365. [PMID: 34335530 DOI: 10.3389/fmicb.2021.698365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
145 Favresse J, Gillot C, Di Chiaro L, Eucher C, Elsen M, Van Eeckhoudt S, David C, Morimont L, Dogné JM, Douxfils J. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses 2021;13:1364. [PMID: 34372570 DOI: 10.3390/v13071364] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 35.0] [Reference Citation Analysis]
146 Hodgson D, Colton H, Hornsby H, Brown R, Mckenzie J, Bradley KL, James C, Lindsey BB, Birch S, Marsh L, Wood S, Bayley M, Dickson G, James DC, Nicklin MJH, Sayers JR, Zafred D, Rowland-Jones SL, Kudesia G, Kucharski A, Darton TC, de Silva TI, Collini PJ; CMMID COVID-19 Working Group. Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. medRxiv 2021:2021. [PMID: 34268521 DOI: 10.1101/2021.07.07.21260151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
147 Perez-Saez J, Zaballa ME, Yerly S, Andrey DO, Meyer B, Eckerle I, Balavoine JF, Chappuis F, Pittet D, Trono D, Kherad O, Vuilleumier N, Kaiser L, Guessous I, Stringhini S, Azman AS; Specchio-COVID19 Study Group. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect 2021:S1198-743X(21)00371-2. [PMID: 34245905 DOI: 10.1016/j.cmi.2021.06.040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
148 Melani RD, Soye BJD, Kafader JO, Forte E, Hollas M, Blagojevic V, Negrão F, McGee JP, Drown B, Lloyd-Jones C, Seckler HS, Camarillo JM, Compton PD, LeDuc RD, Early B, Fellers RT, Cho BK, Mattamana BB, Goo YA, Thomas PM, Ash MK, Bhimalli PP, Al-Harthi L, Sha BE, Schneider JR, Kelleher NL. Next-generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire. medRxiv 2021:2021. [PMID: 34268518 DOI: 10.1101/2021.07.06.21259226] [Reference Citation Analysis]
149 Choudhary HR, Parai D, Dash GC, Peter A, Sahoo SK, Pattnaik M, Rout UK, Nanda RR, Pati S, Bhattacharya D. IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection. Infection 2021. [PMID: 34213733 DOI: 10.1007/s15010-021-01651-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
150 Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A, Lowenton-Spier N, Trestman S, Perry C, Benyamini N, Mittelman M, Tabib Y, Bar Lev T, Zavaro M, Herishanu Y, Luttwak E, Cohen YC. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol 2021. [PMID: 34196388 DOI: 10.1111/bjh.17608] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 39.0] [Reference Citation Analysis]
151 Juncker HG, Mulleners SJ, van Gils MJ, de Groot CJM, Pajkrt D, Korosi A, van Goudoever JB, van Keulen BJ. The Levels of SARS-CoV-2 Specific Antibodies in Human Milk Following Vaccination. J Hum Lact 2021;37:477-84. [PMID: 34176363 DOI: 10.1177/08903344211027112] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
152 Riddell S, Goldie S, McAuley AJ, Kuiper MJ, Durr PA, Blasdell KR, Tachedjian M, Druce JD, Smith TRF, Broderick KE, Vasan SS. Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets. Front Immunol 2021;12:694857. [PMID: 34248993 DOI: 10.3389/fimmu.2021.694857] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
153 Kaneko Y, Sugiyama A, Tanaka T, Fukui K, Taguchi A, Nakayama A, Koga K, Kishi Y, Daming W, Qian C, Xia F, He F, Zheng L, Yu Y, Wada Y, Wada Y, Kodama T, Kawamura T. The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan.. [DOI: 10.1101/2021.06.17.21258858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
154 Lv H, Tsang OT, So RTY, Wang Y, Yuan M, Liu H, Yip GK, Teo QW, Lin Y, Liang W, Wang J, Ng WW, Wilson IA, Peiris JSM, Wu NC, Mok CKP. Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice. Eur J Immunol 2021;51:2296-305. [PMID: 34089541 DOI: 10.1002/eji.202149234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
155 Psichogiou M, Karabinis A, Poulakou G, Antoniadou A, Kotanidou A, Degiannis D, Pavlopoulou ID, Chaidaroglou A, Roussos S, Mastrogianni E, Eliadi I, Basoulis D, Petsios K, Leontis K, Kakkalou E, Protopapas K, Jahaj E, Pratikaki M, Syrigos KN, Lagiou P, Gogas H, Tsiodras S, Magiorkinis G, Paraskevis D, Sypsa V, Hatzakis A. COMPARATIVE IMMUNOGENICITY OF BNT162b2 mRNA VACCINE WITH NATURAL COVID-19 INFECTION.. [DOI: 10.1101/2021.06.15.21258669] [Reference Citation Analysis]
156 Viana J, van Dorp CH, Nunes A, Gomes MC, van Boven M, Kretzschmar ME, Veldhoen M, Rozhnova G. Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat Commun 2021;12:3674. [PMID: 34135335 DOI: 10.1038/s41467-021-23938-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 46.0] [Reference Citation Analysis]
157 Lu Y, Wang J, Li Q, Hu H, Lu J, Chen Z. Advances in Neutralization Assays for SARS‐CoV‐2. Scand J Immunol 2021;94. [DOI: 10.1111/sji.13088] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
158 Huang CG, Dutta A, Huang CT, Chang PY, Hsiao MJ, Hsieh YC, Lin SM, Shih SR, Tsao KC, Yang CT. Relative COVID-19 Viral Persistence and Antibody Kinetics. Pathogens 2021;10:752. [PMID: 34199240 DOI: 10.3390/pathogens10060752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
159 Ramos I, Goforth C, Soares-Schanoski A, Weir DL, Samuels EC, Phogat S, Meyer M, Huang K, Pietzsch CA, Ge Y, Pike BL, Regeimbal J, Simons MP, Termini MS, Vangeti S, Marjanovic N, Lizewski S, Lizewski R, George MC, Nair VD, Smith GR, Mao W, Chikina M, Broder CC, Laing ED, Bukreyev A, Sealfon SC, Letizia AG. Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection. Front Immunol 2021;12:681586. [PMID: 34177926 DOI: 10.3389/fimmu.2021.681586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
160 . Accélérer la vaccination contre la Covid-19. Bull Acad Natl Med 2021;205:662-3. [PMID: 34121753 DOI: 10.1016/j.banm.2021.06.006] [Reference Citation Analysis]
161 Vandergaast R, Carey T, Reiter S, Lathrum C, Lech P, Gnanadurai C, Haselton M, Buehler J, Narjari R, Schnebeck L, Roesler A, Sevola K, Suksanpaisan L, Bexon A, Naik S, Brunton B, Weaver SC, Rafael G, Tran S, Baum A, Kyratsous CA, Peng KW, Russell SJ. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers. mSphere 2021;6:e0017021. [PMID: 34077262 DOI: 10.1128/mSphere.00170-21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
162 Hedges JF, Thompson MA, Snyder DT, Robison A, Taylor MP, Jutila MA. Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination. Vaccines (Basel) 2021;9:587. [PMID: 34199357 DOI: 10.3390/vaccines9060587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
163 Patel MD, Rosenstrom E, Ivy JS, Mayorga ME, Keskinocak P, Boyce RM, Hassmiller Lich K, Smith RL 3rd, Johnson KT, Delamater PL, Swann JL. Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality. JAMA Netw Open 2021;4:e2110782. [PMID: 34061203 DOI: 10.1001/jamanetworkopen.2021.10782] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 50.0] [Reference Citation Analysis]
164 Roifman CM, Vong L. COVID-19 vaccination for patients with primary immunodeficiency. LymphoSign Journal 2021;8:37-45. [DOI: 10.14785/lymphosign-2021-0020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
165 Cantoni D, Mayora-neto M, Nadesalingham A, Wells DA, Carnell GW, Ohlendorf L, Ferarri M, Palmer P, Chan AC, Smith P, Bentley EM, Einhauser S, Wagner R, Page M, Raddi G, Baxendale H, Castillo-olivares J, Heeney J, Temperton N. Neutralisation hierarchy of SARS-CoV-2 Variants of Concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholds.. [DOI: 10.1101/2021.05.24.21257729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
166 Liu Y, Soh WT, Kishikawa JI, Hirose M, Nakayama EE, Li S, Sasai M, Suzuki T, Tada A, Arakawa A, Matsuoka S, Akamatsu K, Matsuda M, Ono C, Torii S, Kishida K, Jin H, Nakai W, Arase N, Nakagawa A, Matsumoto M, Nakazaki Y, Shindo Y, Kohyama M, Tomii K, Ohmura K, Ohshima S, Okamoto T, Yamamoto M, Nakagami H, Matsuura Y, Nakagawa A, Kato T, Okada M, Standley DM, Shioda T, Arase H. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell 2021;184:3452-3466.e18. [PMID: 34139176 DOI: 10.1016/j.cell.2021.05.032] [Cited by in Crossref: 112] [Cited by in F6Publishing: 78] [Article Influence: 112.0] [Reference Citation Analysis]
167 Castillo-olivares J, Wells DA, Ferrari M, Chan A, Smith P, Nadesalingam A, Paloniemi M, Carnell G, Ohlendorf L, Cantoni D, Mayora-neto M, Palmer P, Tonks P, Temperton N, Wagner R, Neckermann P, Peterhoff D, Doffinger R, Kempster S, Otter A, Semper A, Brooks T, Page M, Albecka A, James LC, Briggs J, Schwaeble W, Baxendale H, Heeney J. Towards Internationally standardised humoral Immune Correlates of Protection from SARS-CoV-2 infection and COVID-19 disease.. [DOI: 10.1101/2021.05.21.21257572] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
168 Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau PY, Couture M, D'Aoust MA, Dhaliwall J, Finkle C, Hager K, Mahmood A, Makarkov A, Cheng MP, Pillet S, Schimke P, St-Martin S, Trépanier S, Landry N. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med 2021;27:1071-8. [PMID: 34007070 DOI: 10.1038/s41591-021-01370-1] [Cited by in Crossref: 107] [Cited by in F6Publishing: 114] [Article Influence: 107.0] [Reference Citation Analysis]
169 Mendes-correa MC, Villas-boas LS, Bierrenbach AL, de Paula A, Tozetto-mendoza TR, Leal FE, Freire W, Paiao HGO, Ferraz ABC, Witkin SS. Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant.. [DOI: 10.1101/2021.05.11.21256908] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Yao L, Wang GL, Shen Y, Wang ZY, Zhan BD, Duan LJ, Lu B, Shi C, Gao YM, Peng HH, Wang GQ, Wang DM, Jiang MD, Cao GP, Ma MJ. Persistence of Antibody and Cellular Immune Responses in COVID-19 patients over Nine Months after Infection. J Infect Dis 2021:jiab255. [PMID: 33978754 DOI: 10.1093/infdis/jiab255] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 35.0] [Reference Citation Analysis]
171 Kaplonek P, Wang C, Bartsch Y, Fischinger S, Gorman MJ, Bowman K, Kang J, Dayal D, Martin P, Nowak R, Hsieh CL, Feldman J, Julg B, Nilles EJ, Musk ER, Menon AS, Fischer ES, McLellan JS, Schmidt A, Goldberg MB, Filbin M, Hacohen N, Lauffenburger DA, Alter G. Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19. bioRxiv 2021:2021. [PMID: 34013263 DOI: 10.1101/2021.05.11.443609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
172 Jergović M, Coplen CP, Uhrlaub JL, Nikolich-Žugich J. Immune response to COVID-19 in older adults. J Heart Lung Transplant 2021:S1053-2498(21)02303-2. [PMID: 34140221 DOI: 10.1016/j.healun.2021.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
173 Gangaev A, Ketelaars SLC, Isaeva OI, Patiwael S, Dopler A, Hoefakker K, De Biasi S, Gibellini L, Mussini C, Guaraldi G, Girardis M, Ormeno CMPT, Hekking PJM, Lardy NM, Toebes M, Balderas R, Schumacher TN, Ovaa H, Cossarizza A, Kvistborg P. Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. Nat Commun 2021;12:2593. [PMID: 33972535 DOI: 10.1038/s41467-021-22811-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 48.0] [Reference Citation Analysis]
174 Charlton C, Kanji J, Tran V, Kus J, Gubbay J, Osiowy C, Robinson J, Sekirov I, Drebot M, Hatchette T, Stein D, El-Gabalawy N, Lang A, Jiao L, Levett P, Wood H, Therrien C, Lindsay LR, Morshed M, Forbes J, Dibernardo A. Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. Can Commun Dis Rep 2021;47:171-83. [PMID: 34035663 DOI: 10.14745/ccdr.v47i04a01] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
175 Kurup D, Schnell MJ. SARS-CoV-2 vaccines - the biggest medical research project of the 21st century. Curr Opin Virol 2021;49:52-7. [PMID: 34049261 DOI: 10.1016/j.coviro.2021.04.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
176 Kruse RL, Huang Y, Lee A, Zhu X, Shrestha R, Laeyendecker O, Littlefield K, Pekosz A, Bloch EM, Tobian AAR, Wang ZZ. A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels. medRxiv 2021:2021. [PMID: 33972952 DOI: 10.1101/2021.05.01.21256452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Laing ED, Epsi NJ, Richard SA, Samuels EC, Wang W, Vassell R, Ewing DF, Herrup R, Sterling SL, Lindholm DA, Millar EV, Maves RC, Larson DT, Colombo RE, Chi S, Madar C, Lalani T, Ganesan A, Fries A, Colombo CJ, Mende K, Simons MP, Schully KL, Weiss CD, Tribble DR, Agan BK, Pollett SD, Broder CC, Burgess TH, for the EPICC Study team. SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity.. [DOI: 10.1101/2021.04.27.21256207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
178 Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J, Hillebrandt J, Ritchie A, Rabl D, Ostermann PN, Robitzsch R, Hauka S, Walker A, Menne C, Grutza R, Timm J, Adams O, Schaal H. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis 2021:ciab381. [PMID: 33906236 DOI: 10.1093/cid/ciab381] [Cited by in Crossref: 182] [Cited by in F6Publishing: 241] [Article Influence: 182.0] [Reference Citation Analysis]
179 Casel MAB, Rollon RG, Choi YK. Experimental Animal Models of Coronavirus Infections: Strengths and Limitations. Immune Netw 2021;21:e12. [PMID: 33996168 DOI: 10.4110/in.2021.21.e12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
180 Garrido C, Hurst JH, Lorang CG, Aquino JN, Rodriguez J, Pfeiffer TS, Singh T, Semmes EC, Lugo DJ, Rotta AT, Turner NA, Burke TW, McClain MT, Petzold EA, Permar SR, Moody MA, Woods CW, Kelly MS, Fouda GG. Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. medRxiv 2021:2021. [PMID: 33907760 DOI: 10.1101/2021.04.17.21255663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
181 Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-González A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C, Federman S, Cheng J, Balcerek J, Taylor J, Streithorst JA, Miller S, Sreekumar B, Chen PY, Schulze-Gahmen U, Taha TY, Hayashi JM, Simoneau CR, Kumar GR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Frankino PA, Shivram H, Lareau LF, Wyman SK, Ott M, Andino R, Chiu CY. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 2021;184:3426-3437.e8. [PMID: 33991487 DOI: 10.1016/j.cell.2021.04.025] [Cited by in Crossref: 278] [Cited by in F6Publishing: 185] [Article Influence: 278.0] [Reference Citation Analysis]
182 Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan H, Center RJ, Li F, Grimley SL, Wines BD, Nguyen TH, Mordant FL, Rowntree LC, Cheng AC, Doolan DL, Bond K, Hogarth PM, Mcquilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DF, Anderson DA, Godfrey DI. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.. [DOI: 10.1101/2021.04.12.21255368] [Reference Citation Analysis]
183 Zha L, Chang X, Zhao H, Mohsen MO, Hong L, Zhou Y, Chen H, Liu X, Zhang J, Li D, Wu K, Martina B, Wang J, Vogel M, Bachmann MF. Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. Vaccines (Basel) 2021;9:395. [PMID: 33923573 DOI: 10.3390/vaccines9040395] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
184 Křupka M, Kosztyu P, Račanský M, Schovánek J, Sloupenská K, Strojil J, Raška M. Possibilities and principles of vaccination against COVID-19. Prakticke lekarenstvi 2021;17:7-13. [DOI: 10.36290/lek.2021.001] [Reference Citation Analysis]
185 Letizia AG, Ge Y, Vangeti S, Goforth C, Weir DL, Kuzmina NA, Balinsky CA, Chen HW, Ewing D, Soares-Schanoski A, George MC, Graham WD, Jones F, Bharaj P, Lizewski RA, Lizewski SE, Marayag J, Marjanovic N, Miller CM, Mofsowitz S, Nair VD, Nunez E, Parent DM, Porter CK, Santa Ana E, Schilling M, Stadlbauer D, Sugiharto VA, Termini M, Sun P, Tracy RP, Krammer F, Bukreyev A, Ramos I, Sealfon SC. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med 2021;9:712-20. [PMID: 33865504 DOI: 10.1016/S2213-2600(21)00158-2] [Cited by in Crossref: 87] [Cited by in F6Publishing: 55] [Article Influence: 87.0] [Reference Citation Analysis]
186 Siggins MK, Thwaites RS, Openshaw PJM. Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses. Trends Microbiol 2021;29:648-62. [PMID: 33896688 DOI: 10.1016/j.tim.2021.03.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 29.0] [Reference Citation Analysis]
187 Kreuzberger N, Hirsch C, Vanshylla K, Di Cristanziano V, Dorando E, Khosravi Z, Neidhardt M, Salomon S, Monsef I, Lange B, Skoetz N. Persistence of immunoglobulin G after natural infection with SARS-CoV-2. Cochrane Database of Systematic Reviews 2021. [DOI: 10.1002/14651858.cd014946] [Reference Citation Analysis]
188 Su Y, Yuan D, Chen DG, Wang K, Choi J, Dai CL, Hong S, Zhang R, Xie J, Li S, Scherler K, Pavlovitch-bedzyk AJ, Dong S, Lausted C, Ng RH, Lee I, Fallen S, Kornilov SA, Baloni P, Duvvuri VR, Anderson KG, Li J, Yang F, Rostomily C, Troisch P, Smith B, Zhou J, Mackay S, Murray K, Edmark R, Jones L, Zhou Y, Rowen L, Liu R, Chour W, Berrington WR, Wallick JA, Algren HA, Wrin T, Petropoulos CJ, Wei W, Price ND, Subramanian N, Hadlock J, Magis AT, Ribas A, Lanier LL, Boyd SD, Bluestone JA, Hood L, Gottardo R, Greenberg PD, Davis MM, Goldman JD, Heath JR, the ISB-Swedish COVID19 Biobanking Unit. Heterogeneous immunological recovery trajectories revealed in post-acute COVID-19.. [DOI: 10.1101/2021.03.19.21254004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Perez-saez J, Zaballa M, Yerly S, Andrey DO, Meyer B, Eckerle I, Balavoine J, Chappuis F, Pittet D, Trono D, Kherad O, Vuilleumier N, Kaiser L, Guessous I, Stringhini S, Azman AS, for the Specchio-COVID19 Study Group. Persistence and detection of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance.. [DOI: 10.1101/2021.03.16.21253710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
190 Wu JT, Leung K, Lam TTY, Ni MY, Wong CKH, Peiris JSM, Leung GM. Nowcasting epidemics of novel pathogens: lessons from COVID-19. Nat Med 2021;27:388-95. [PMID: 33723452 DOI: 10.1038/s41591-021-01278-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
191 Lombardi A, Bozzi G, Ungaro R, Villa S, Castelli V, Mangioni D, Muscatello A, Gori A, Bandera A. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. Front Immunol 2021;12:657711. [PMID: 33777055 DOI: 10.3389/fimmu.2021.657711] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 28.0] [Reference Citation Analysis]
192 De Giorgi V, West KA, Henning AN, Chen L, Holbrook MR, Gross R, Liang J, Postnikova E, Trenbeath J, Pogue S, Scinto T, Alter HJ, Cantilena CC. Anti-SARS-CoV-2 Serology persistence over time in COVID-19 Convalescent Plasma Donors. medRxiv 2021:2021. [PMID: 33758897 DOI: 10.1101/2021.03.08.21253093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
193 Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-González A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C, Federman S, Cheng J, Balcerek J, Taylor J, Streithorst JA, Miller S, Kumar GR, Sreekumar B, Chen PY, Schulze-Gahmen U, Taha TY, Hayashi J, Simoneau CR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Lareau LF, Frankino PA, Shivram H, Wyman SK, Ott M, Andino R, Chiu CY. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv 2021:2021. [PMID: 33758899 DOI: 10.1101/2021.03.07.21252647] [Cited by in Crossref: 115] [Cited by in F6Publishing: 117] [Article Influence: 115.0] [Reference Citation Analysis]
194 Favresse J, Eucher C, Elsen M, Gillot C, Van Eeckhoudt S, Dogné JM, Douxfils J. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021;9:556. [PMID: 33800489 DOI: 10.3390/microorganisms9030556] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 41.0] [Reference Citation Analysis]
195 Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J Jr, Trinh L, Wrin T, Petroplolous CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. medRxiv 2021:2021. [PMID: 33688675 DOI: 10.1101/2021.03.03.21251639] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
196 Lefebvre M, Vignier N, Pitard B, Botelho-Nevers E, Wyplosz B, Cohen R, Epaulard O; SPILF Vaccination Prevention group. COVID-19 vaccines: Frequently asked questions and updated answers. Infect Dis Now 2021;51:319-33. [PMID: 33681861 DOI: 10.1016/j.idnow.2021.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
197 Delbue S, D'Alessandro S, Signorini L, Dolci M, Pariani E, Bianchi M, Fattori S, Modenese A, Galli C, Eberini I, Ferrante P. Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein. Emerg Microbes Infect 2021;10:252-5. [PMID: 33525998 DOI: 10.1080/22221751.2021.1884003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
198 Borena W, Bánki Z, Bates K, Winner H, Riepler L, Rössler A, Pipperger L, Theurl I, Falkensammer B, Ulmer H, Walser A, Pichler D, Baumgartner M, Schönherr S, Forer L, Knabl L, Würzner R, Laer DV, Paetzold J, Kimpel J. Follow-up study in the ski-resort Ischgl: Antibody and T cell responses to SARS-CoV-2 persisted for up to 8 months after infection and transmission of virus was low even during the second infection wave in Austria.. [DOI: 10.1101/2021.02.19.21252089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Lv H, Tsang OT, So RTY, Wang Y, Yuan M, Liu H, Yip GK, Teo QW, Lin Y, Liang W, Wang J, Ng WW, Wilson IA, Peiris JSM, Wu NC, Mok CKP. Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2.. [DOI: 10.1101/2021.02.17.431722] [Reference Citation Analysis]
200 Cohen CA, Li AP, Hachim A, Hui DS, Kwan MY, Tsang OT, Chiu SS, Chan WH, Yau YS, Kavian N, Ma FN, Lau EH, Cheng SM, Poon LL, Peiris JM, Valkenburg SA. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. medRxiv 2021:2021. [PMID: 33564773 DOI: 10.1101/2021.02.02.21250988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
201 Oyewole AO, Barrass L, Robertson EG, Woltmann J, O'Keefe H, Sarpal H, Dangova K, Richmond C, Craig D. COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications. Diagnostics (Basel) 2021;11:182. [PMID: 33513988 DOI: 10.3390/diagnostics11020182] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
202 Lippi G, Sciacovelli L, Trenti T, Plebani M. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination. Clinical Chemistry and Laboratory Medicine (CCLM) 2021;59:1333-5. [DOI: 10.1515/cclm-2021-0038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
203 Chhabra M, Arora S, Shulania A, Panesar S, Chauhan A, Ganguly K, Achra A, Nirmal K, Duggal N. Severe acute respiratory syndrome coronavirus-2 IgG antibodies among health-care workers in a tertiary care hospital in Delhi India. J Patient Saf Infect Control 2021;9:48. [DOI: 10.4103/jpsic.jpsic_15_21] [Reference Citation Analysis]
204 [DOI: 10.1101/2021.04.17.440246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
205 [DOI: 10.1101/2021.03.24.21254188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]